BitGo Establishes Official Presence in Brazil to Offer Crypto Custody and Digital Treasury Services to Financial Institutions
With over a decade of experience in custody solutions, products, and services for digital assets, BitGo believes that ongoing discussions in Brazil are moving toward requiring local management of cryptographic keys, a capability the company is already prepared to deliver. By establishing a local presence, BitGo aims to ensure compliance, security, and sovereignty in providing services to financial institutions such as banks, brokerages, and asset managers.
The decision to enter the Brazilian market follows the company's receipt of the MiCa license in Germany, one of the industry's most rigorous certifications, which enables BitGo to operate under European standards. The current focus is on building a strong foundation in Brazil, regardless of the country's final regulatory outcome.
'We want banks to see us as allies. We are prepared to meet any demands that arise, with security, technology, and respect for local laws. Even if the legislation takes another path, we will remain here as partners of Brazilian institutions,' says Luis Ayala, BitGo's LatAm Director.
Recently, the company expanded its operations with a full portfolio of corporate treasury solutions for digital assets. In addition to insured cold storage custody and OTC trading for institutional investors, BitGo offers automated treasury workflows, audit-ready APIs, and highly specialized technical support. These services were developed for companies seeking not only security but also efficiency and control in their crypto asset operations.
With the new Brazilian operation, these services are now offered through a truly localized approach, taking into account Brazil's economic, regulatory, and cultural context. BitGo is prepared to support companies that view cryptocurrencies as a strategic alternative for cash diversification, asset protection, and capital growth. The company believes that by providing technical and regulatory support tailored to the national reality, it is possible to unlock institutional use of digital assets, contributing to market maturity and the development of new, more decentralized, robust, and trend-globally-aligned financial management.
'BitGo Brasil represents not just a geographical expansion but our commitment to the sustainable development of the local crypto ecosystem, offering robust infrastructure tailored to Brazil's economic and regulatory landscape, with a focus on institutional trust,' concludes Luis Ayala.
About BitGo
BitGo is the leading infrastructure provider of digital asset solutions, delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. Since our founding in 2013, we have focused on enabling our clients to securely navigate the digital asset space. With a large global presence through multiple regulated entities, BitGo serves thousands of institutions, including many of the industry's top brands, exchanges, and platforms, as well as millions of retail investors worldwide. As the operational backbone of the digital economy, BitGo handles a significant portion of Bitcoin network transactions and is the largest independent digital asset custodian, and staking provider, in the world. For more information, visit www.bitgo.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407. The CLEAR-DE (Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients with non-proliferative diabetic retinopathy (NPDR). The progression to a Phase IIb clinical study follows encouraging results from Exonate's Phase Ib/IIa study in March 2024. In the study, lead candidate EXN407 met its primary safety and tolerability endpoints, with no drug-related serious adverse events, and high patient compliance. Importantly, exploratory efficacy signals showed a reduction in vascular leakage, a key pathological driver in diabetic retinopathy. The Phase IIb trial to investigate the efficacy of EXN407 in NPDR patients is planned to begin in early 2026, with 140 patients currently enrolled across multiple sites in Australia, the Middle East and China. Diabetic retinopathy (DR) is a leading cause of vision loss globally. An estimated one-third of the nearly 500 million people living with diabetes are affected by NPDR, the early stage of diabetic eye disease, which can lead to more severe, vision-threatening complications. Current therapeutic approaches involve monthly intraocular injections, initiated only after symptoms appear. This limits opportunities for early therapeutic benefit, and due to the invasive nature and frequency, is often deferred until irreversible damage has occurred. EXN407 is a first-in-class, twice-daily topical formulation of a selective SRPK1 inhibitor – a minimally-invasive approach with potential to become the first effective eye-drop therapy for NPDR and diabetic macular oedema (DME). Designed to modulate expression of vascular endothelial growth factor (VEGF) via alternative mRNA splicing, EXN407 selectively inhibits the pro-angiogenic isoforms that drive disease progression, causing abnormal and leaky blood vessel formation in the retina. ' The Phase Ib/IIa data demonstrated the clear potential of EXN407 as a non-invasive treatment for diabetic eye disease, ' said Dr. Catherine Beech, Chief Executive Officer of Exonate. ' This therapy could transform the treatment landscape for early-stage disease by providing clinical benefit while avoiding the burden of injections, representing a significant advancement for patients and physicians alike. We're excited to progress to the CLEAR-DE Phase IIb trial and are actively seeking strategic partners to support its execution.' For more information about Exonate's pipeline and clinical development plans, please visit:
Wall Street Journal
28 minutes ago
- Wall Street Journal
Podcast: What to Make of the U.S.-EU Deal
Business leaders on both sides of the Atlantic welcomed a trade deal between the U.S. and European Union, despite pushback from Europe. White House economic policy reporter Brian Schwartz discusses how the deal came to be and the reaction from around the world. 🎧 Listen to the What's News podcast here.
Wall Street Journal
28 minutes ago
- Wall Street Journal
Heard in the Street Monday Recap: Done Deal
President Trump reached a trade deal with the European Union over the weekend. The deal imposes a 15% baseline tariff on products imported from the bloc, including cars. The EU agreed to buy $750 billion of U.S. energy products and invest $600 billion in the U.S., Trump said. Stocks affected by the deal, including chip and auto companies, moved. Semiconductor-equipment manufacturer ASML rose 2.6% after the deal exempted its products from levies. However, carmakers dropped, with BMW down 3.3% and Mercedes falling 3.2% in Europe. Analysts were skeptical that the energy purchase targets would be achievable. Samsung and Tesla stocks rose after the companies reached a chip-supply deal. The multiyear agreement, worth more than $16 billion, involves Samsung making key chips for Tesla's electric cars. Tesla ended the session up 3%.
